search
Back to results

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Primary Purpose

Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients

Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Metformin Pill
Vildagliptin 50 mg
Sponsored by
MTI University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients focused on measuring diabetes, Metformin, vildagliptin, hypertension, cardiovascular risk

Eligibility Criteria

40 Years - 60 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients suffering from moderate HTN and DM, their HbA1c ≥ 7 and age range between 40-60 years, treatment with diet alone, any combination of oral antidiabetic agents and/or insulin before admission

Exclusion Criteria:

  • Clinical evidence of ischemic heart disease, chronic obstructive pulmonary disease, presence of diabetic ketoacidosis (DKA), patients admitted to intensive care unit (ICU), subjects expected to undergo surgery during the study period, patients with clinically relevant hepatic disease, impaired renal function (serum creatinine ≥3.0 mg/dL), systemic infections or pregnancy. Also, patients on medications known to interfere with the blood glucose level (either increasing or decreasing) were excluded from the study.

Sites / Locations

  • National institute of diabetes and endocrinology

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

No Intervention

Other

Other

Arm Label

Healthy control

diabetic hypertensive recently diagnosed patients

Metformin treated group

Vildagliptin treated group

Arm Description

healthy volunteers not suffering from diabetes or hypertension

recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet

diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes

diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes

Outcomes

Primary Outcome Measures

benefit of reducing hypertension in diabetic hypertensive patients
blood pressure will be measured
benefit of lowering cardiovascular risks for diabetic hypertensive patients
total lipid profile will be measured
benefit of improving the condition of elevated blood pressure in patients through neovascularization
vascular endothelial growth factor level in serum will be measured

Secondary Outcome Measures

reducing obesity for diabetic patients
difference in body weight at the beginning and the end of the study will be measured
comparing the anti-hyperglycemic effect of each drug for diabetic hypertensive patients
glycated hemoglobin will be measured

Full Information

First Posted
August 10, 2017
Last Updated
August 15, 2017
Sponsor
MTI University
search

1. Study Identification

Unique Protocol Identification Number
NCT03253562
Brief Title
Metformin Versus Vildagliptin for Diabetic Hypertensive Patients
Official Title
Comparative Efficacy and Safety of Vildagliptin Versus Metformin in Reduction of Cardiovascular Complications in Type 2 Diabetic Patients With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 1, 2017 (Actual)
Primary Completion Date
August 1, 2017 (Actual)
Study Completion Date
August 1, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
MTI University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a controlled study to measure the efficacy of using metformin or vildagliptin for type 2 diabetic patients who suffers from hypertension to reduce cardiovascular risk resulting from both diabetes and hypertension using different parameters measuring
Detailed Description
Several studies indicated that type 2 diabetes mellitus and hypertension are associated with increased cardiovascular complications. Recently, studies suggest that metformin and vildagliptin can reduce cardiovascular complications in diabetic patients with unclear mechanisms. This work aimed to determine the effect of metformin and vildagliptin on diabetic-hypertensive patients. Patients were allocated into four groups: groupI: healthy volunteers, groupII: patients recently diagnosed with their hypertension and diabetes, groupIII: patients treated with captopril (25mg once daily) for their hypertension in addition to metformin (1000mg bid) groupIV: patients treated with captopril (25mg bid) for hypertension in addition to vildagliptin (50mg bid). At the end of the therapeutic period, then total cholesterol, LDL,serum Creatinine level, blood pressure and vascular endothelial growth factor (VEGF) levels in serum will be measured for different groups to estimate the benefits of one drug over the other one in protecting against cardiovascular risks for diabetic hypertensive patients..

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
Keywords
diabetes, Metformin, vildagliptin, hypertension, cardiovascular risk

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy control
Arm Type
No Intervention
Arm Description
healthy volunteers not suffering from diabetes or hypertension
Arm Title
diabetic hypertensive recently diagnosed patients
Arm Type
No Intervention
Arm Description
recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
Arm Title
Metformin treated group
Arm Type
Other
Arm Description
diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
Arm Title
Vildagliptin treated group
Arm Type
Other
Arm Description
diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
Intervention Type
Drug
Intervention Name(s)
Metformin Pill
Intervention Description
a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
Intervention Type
Drug
Intervention Name(s)
Vildagliptin 50 mg
Intervention Description
Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
Primary Outcome Measure Information:
Title
benefit of reducing hypertension in diabetic hypertensive patients
Description
blood pressure will be measured
Time Frame
6 months
Title
benefit of lowering cardiovascular risks for diabetic hypertensive patients
Description
total lipid profile will be measured
Time Frame
6 months
Title
benefit of improving the condition of elevated blood pressure in patients through neovascularization
Description
vascular endothelial growth factor level in serum will be measured
Time Frame
6 months
Secondary Outcome Measure Information:
Title
reducing obesity for diabetic patients
Description
difference in body weight at the beginning and the end of the study will be measured
Time Frame
6months
Title
comparing the anti-hyperglycemic effect of each drug for diabetic hypertensive patients
Description
glycated hemoglobin will be measured
Time Frame
6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients suffering from moderate HTN and DM, their HbA1c ≥ 7 and age range between 40-60 years, treatment with diet alone, any combination of oral antidiabetic agents and/or insulin before admission Exclusion Criteria: Clinical evidence of ischemic heart disease, chronic obstructive pulmonary disease, presence of diabetic ketoacidosis (DKA), patients admitted to intensive care unit (ICU), subjects expected to undergo surgery during the study period, patients with clinically relevant hepatic disease, impaired renal function (serum creatinine ≥3.0 mg/dL), systemic infections or pregnancy. Also, patients on medications known to interfere with the blood glucose level (either increasing or decreasing) were excluded from the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hekma A Abdel-Latif, Professor
Organizational Affiliation
cairo university faculty of pharmacy
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Abdel Rahman M El-Naggar, Professor
Organizational Affiliation
Cairo University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mohammed F Elyamany, assistant professor
Organizational Affiliation
cairo university faculty of pharmacy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Soha O Hassanin, lecturer
Organizational Affiliation
MTI unuversity faculty of pharmacy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Atef Bassyouni, Professor
Organizational Affiliation
National institute of diabetes and endocrinology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Dalia K Zaafar, assistant lecturer
Organizational Affiliation
MTI unuversity faculty of pharmacy
Official's Role
Principal Investigator
Facility Information:
Facility Name
National institute of diabetes and endocrinology
City
Cairo
ZIP/Postal Code
11311
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

We'll reach out to this number within 24 hrs